Actuate Therapeutics, Inc. Common stock ACTU R2K
Company Overview
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -3.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -3.42% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -72.10% |
| 6 Months: | -71.82% |
| 3 Months: | -4.95% |
| 1 Month: | -13.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -3.4% CAGR over 5 years.
- Trading 80.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACTU Actuate Therapeutics, Inc. Common stock R2K | 1.73 | -1.77 | $41.39M | 0.00% | - | - | - | -3.42% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 6.37M | 5.97M | 5.47M | 4.69M | 5.71M |
| Operating Income | - | -5.58M | -6.48M | -7.77M | -5.44M | - | - | -6.37M | -5.97M | -5.47M | -4.69M | -5.71M |
| EBITDA | - | - | - | - | - | - | - | -6.31M | -5.94M | -5.40M | -4.55M | -5.62M |
| Interest Expense | - | - | - | - | - | - | - | 5.06K | 5.06K | 5.06K | 5.06K | 5.06K |
| Pretax Income | - | - | - | - | - | - | - | -6.32M | -5.95M | -5.41M | -4.55M | -5.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.27M | -5.52M | -6.34M | -8.30M | -6.57M | - | - | -6.32M | -5.95M | -5.41M | -4.55M | -5.63M |
| Diluted EPS | - | -3.88 | -4.31 | -5.40 | -4.20 | -0.55 | - | -0.32 | -0.30 | -0.25 | - | -0.24 |
| R&D Expense | - | 4.78M | 5.76M | 6.86M | 4.37M | 3.76M | - | 3.22M | 2.76M | 2.18M | - | 2.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.50M |
| Operating Income | -20.21M | -24.97M | -25.16M | -22.50M |
| EBITDA | -20.14M | -24.70M | -27.27M | -22.21M |
| Interest Expense | 16.20K | 43.64K | 18.72K | 20.25K |
| Pretax Income | -20.16M | -24.74M | -27.29M | -22.23M |
| Tax Provision | - | - | - | - |
| Net Income | -20.16M | -24.74M | -27.29M | -22.23M |
| Diluted EPS | -1.34 | -1.29 | -3.26 | -1.06 |
| R&D Expense | - | 21.71M | 18.68M | 10.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 20.48M | 3.00M | 9.32M | 14.04M |
| Current Assets | 20.48M | 3.00M | 9.21M | 13.64M |
| Cash & Equivalents | 20.45M | 2.96M | 8.64M | 13.16M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 95.79M | 102.62M | 9.21M | 6.11M |
| Current Liabilities | 4.34M | 6.92M | 8.80M | 5.71M |
| Long Term Debt | - | - | - | - |
| Total Debt | - | - | - | - |
| Total Equity | -75.31M | -99.63M | 104.19K | 7.92M |
| Shares Outstanding | 19.11M | 19.11M | 19.53M | 23.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -17.79M | -21.63M | -21.84M | -19.21M |
| Investing Cash Flow | - | - | - | - |
| Financing Cash Flow | 19.26M | 4.13M | 27.53M | 23.72M |
| Capital Expenditure | - | - | - | - |
| Free Cash Flow | -17.79M | -21.63M | -21.84M | -19.21M |
| Net Change in Cash | 1.46M | -17.49M | 5.68M | 4.52M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 26.8% | 24.8% | -26,189.1% | -280.5% |
| ROCE % | -125.2% | 636.3% | -4,876.6% | -270.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACTU
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham - Elraglusib will be assessed in combination with dinu…
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib…
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, an…
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapiesCHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Ac…
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate >20% in elraglusib arm compared to 4% in …
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 /Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly sele…
ACTU — Frequently Asked Questions
What is the current share price of Actuate Therapeutics, Inc. Common stock (ACTU)?
As of 2026-07-14 21:23 PDT, Actuate Therapeutics, Inc. Common stock (ACTU) trades at $1.73 on NasdaqGM. Its 52-week range is $1.21 to $8.72.
What is the market capitalisation of ACTU?
Actuate Therapeutics, Inc. Common stock (ACTU) has a market capitalisation of $41.39M on NasdaqGM.
What is the P/E ratio of ACTU?
ACTU trades at a trailing price-to-earnings (P/E) ratio of -1.77. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 12.62.
Is ACTU a good stock to buy?
This page provides a data-driven analysis of Actuate Therapeutics, Inc. Common stock (ACTU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.